Delving into the Latest Updates on ADUS-100 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [2]

Target

STING

Action

agonists

Mechanism

STING agonists(Stimulator of interferon genes agonists)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

BRAF V600E Mutation-Positive MelanomaSoft Tissue Sarcoma

Inactive Indication

Head and neck cancer metastaticLymphomaRecurrent Head and Neck Carcinoma

Originator Organization

Aduro BioTech, Inc.

Active Organization

National Cancer Center Korea

Brown University

Inactive Organization

Novartis Pharmaceuticals Corp.

Chinook Therapeutics, Inc.

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC20H24N10O10P2S2

InChIKeyIZJJFUQKKZFVLH-YBVMPXGUSA-N

CAS Registry1638241-89-0

View All Structures (2)

ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. The population will consist of adults with PD-L1 positive recurrent or metastatic HNSCC.

Start Date26 Aug 2019

Sponsor / Collaborator

Chinook Therapeutics, Inc.

NCT03172936

/ TerminatedPhase 1

A Phase Ib, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

Start Date08 Sep 2017

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT02675439

/ TerminatedPhase 1

A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection as a single agent and in combination with ipilimumab.

Start Date28 Apr 2016

Sponsor / Collaborator

Chinook Therapeutics, Inc.

[+1]

100 Clinical Results associated with ADUS-100

Login to view more data

100 Translational Medicine associated with ADUS-100

Login to view more data

100 Patents (Medical) associated with ADUS-100

Login to view more data

79

Literatures (Medical) associated with ADUS-100

14 Jan 2025·Future Oncology

Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors

Article

Author: Kitano, Shigehisa ; Alonso, Guzman ; Berz, David ; Gambardella, Valentina ; Schmohl, Michael ; Gutierrez, Martin E. ; Moreno, Irene ; Parkes, Eileen E. ; Barrueco, José ; LoRusso, Patricia ; Fernandez, Natalia ; Harrington, Kevin ; Doi, Toshihiko

BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies.Clinical Trial number: NCT05471856.

01 Jan 2025·Vaccine

Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum

Article

Author: Jaras Salas, Ian ; Esser-Kahn, Aaron P ; Kim, Marie ; Darville, Toni ; Girardi, Jenna ; Wu, Manhong ; Polson, A. Grace ; Polson, A Grace ; Lammert, Sarah Mae ; Poston, Taylor B ; Esser-Kahn, Aaron P. ; Yount, Kacy S ; Rozzelle, James ; Zwarycz, Peter ; Yount, Kacy S. ; Fairman, Jeff ; Hanlan, Courtne ; Poston, Taylor B. ; Bruno, Tony ; Arroyo, Daisy

Chlamydia trachomatis (Ct) is the most common bacterial sexually transmitted infection globally, and a vaccine is urgently needed to stop transmission and disease. Chlamydial Protease Activity Factor (CPAF) is an immunoprevalent and immunodominant antigen for CD4 T cells and B cells, which makes it a strong vaccine candidate. Due to the tolerogenic nature of the female genital tract (FGT) and its lack of secondary lymphoid tissue, effective induction of protective cell-mediated immunity will likely require potent and safe mucosal adjuvants. To address this need, we produced CPAF in a cell-free protein synthesis platform and adjuvanted it with the TLR9-agonist CpG1826, a synthetic cyclic-di-AMP (CDA) STING (stimulator of interferon genes) agonist ADU-S100, and/or the squalene oil-in-water nanoemulsion, AddaS03. We determined that intranasal immunization with CPAF plus ADU-S100 was well tolerated in female mice, induced CD4 T cells characterized by TNFα production alone or in combination with IL-17 A or IFNγ, significantly reduced bacterial shedding, and shortened the duration of infection in mice intravaginally challenged with Chlamydia muridarum. These data demonstrate the potential for CDA as a mucosal adjuvant for vaccines against Chlamydia genital tract infection.

31 Dec 2024·OncoImmunology

Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34

Article

Author: Van Moer, Kris ; Bartolini, Elisabetta ; Janji, Bassam

We have recently demonstrated that inhibiting VPS34 enhances T-cell-recruiting chemokines through the activation of the cGAS/STING pathway using the STING agonist ADU-S100. Combining VPS34 inhibitors with ADU-S100 increased cytokine release and improved tumor control in mouse models, suggesting a potential synergy between VPS34 inhibition and therapies based on STING agonists.

100 Deals associated with ADUS-100

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14722

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and neck cancer metastatic	Phase 2	United States	Chinook Therapeutics, Inc.	26 Aug 2019
Recurrent Head and Neck Carcinoma	Phase 2	United States	Chinook Therapeutics, Inc.	26 Aug 2019
Solid tumor	Phase 2	Spain	Novartis Pharmaceuticals Corp.	08 Sep 2017
Solid tumor	Phase 2	Netherlands	Novartis Pharmaceuticals Corp.	08 Sep 2017
Solid tumor	Phase 2	Switzerland	Novartis Pharmaceuticals Corp.	08 Sep 2017
Solid tumor	Phase 2	Japan	Novartis Pharmaceuticals Corp.	08 Sep 2017
Solid tumor	Phase 2	Germany	Novartis Pharmaceuticals Corp.	08 Sep 2017
Solid tumor	Phase 2	United States	Novartis Pharmaceuticals Corp.	08 Sep 2017
Solid tumor	Phase 2	Canada	Novartis Pharmaceuticals Corp.	08 Sep 2017
Lymphoma	Phase 2	United States	Chinook Therapeutics, Inc.	28 Apr 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02675439 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Solid tumor \| Lymphoma	47	MIW815	(wdrihgelrh) = pyrexia 17%, chills 15%, injection-site pain 15% iougklkspj (ueplfqvohw )	Positive	15 Feb 2022
NCT03937141 (CTgov)	Phase 2	Recurrent Head and Neck Carcinoma \| Head and neck cancer metastatic	16	ADU-S100	hcvsufvtxo(zlhhgeezjs) = dsjtovvqio xftrhrdpbw (osuctxxgzx, dyzbnuecnx - nymdthtjyq) View more	-	03 Jan 2022
NCT03937141 (ESMO_IO2020) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck First line PD-L1 Positive	-	ADU-S100+Pembrolizumab	(lzuajvbxru) = 4 PR ( 3 confirmed), 1 SD and 3 PD graibxkezr (apflbjpnoj ) View more	Positive	09 Dec 2020